Ufraktioneret og lavmolekylært heparin ved akutte koronare syndromer - en gennemgang af et Cochrane-review

Ugeskrift for Laeger

Volumn 172, Issue 42, 2010, Pages 2888-2891

  Husted, Steen Elkjær ^a   Nielsen, Hans Kræmmer ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HORSENS REGIONAL HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ACUTE CORONARY SYNDROME; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; PRACTICE GUIDELINE; REVIEW; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; ANTICOAGULANTS; ASPIRIN; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; PLACEBOS; PRACTICE GUIDELINES AS TOPIC;

EID: 78149393188     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. De Caterina R, Husted S, Wallentin L et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007;28:880-913.
2. Murphy SA, Gibson CM, Morrow DA et al. Efficacy and safety of the lowmo lecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007;28:2077-86.
3. Théroux P, Waters D, Qiu S et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88:2045-8.
4. Magee KD, Campbell SG, Moher D et al. Heparin versus placebo for acute coronary syndromes. Cochrane Database Syst Rev 2008;(2):CD003462.
5. Eikelboom JW, Anand SS, Malmberg K et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-42.
6. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29:43-8.
7. Husted SE, Wallentin L, Lagerqvist B et al. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J 2002 23:1213-8.
8. Katsouras C, Michalis LK, Papamichael N et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months. Am Heart J 2005;150:385-91.
9. Magee KD, Sevcik W, Moher D et al. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Database Syst Rev 2003;(1):CD002132.
10. Eikelboom J, Guyatt G, Hirsh J. Guidelines for anticoagulant use in acute coronary syndromes. Lancet 2008;371:1559-61.